(News Bulletin 247) – GSK announced Thursday that it has recorded positive results in a phase III clinical study devoted to its experimental ‘5-in-1’ vaccine against the different strains of meningitis.
The British pharmaceutical company emphasizes that the trial has established the non-inferiority of the product compared to the anti-meningococcal vaccines already approved.
The study, which started in 2020, recruited 3,650 children, adolescents and young adults aged 10 to 25 in Canada, the United States, Europe, Turkey and Australia.
This vaccine project was developed knowing that five serogroups are the cause of all cases of invasive meningococcal disease, but that no 5-in-1 vaccine currently exists.
While invasive meningococcal disease is uncommon, it is the leading cause of bacterial meningitis, a disease leading to death in about one in 10 cases, even if appropriate treatment is given.
In addition, approximately 20% of those affected are at risk of having a significant physical or neurological impairment over time, such as loss of a limb, hearing loss or seizures.
In a separate press release, GSK indicates that the Chinese health authorities have agreed to look into the file of a possible marketing of Nucala in the maintenance treatment of severe hypereosinophilic asthma.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
